Clinical Trial

Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy

Study acronym: STRONGER
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated April 10, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
STRONGER is an international, investigator initiated and conducted, pragmatic clinical trial to determine whether 40mg atorvastatin daily can improve neurocognitive function in adults with long COVID neurological symptoms. The objective is to determine effectiveness of treatment with 40mg atorvastatin over 12 months on attenuating cognitive decline and neuroinflammatory biomarkers in adults with long COVID neurological symptoms. The study design is a prospective, randomised, open-label, blinded endpoint (PROBE) study of atorvastatin 40mg on top of standard care, in patients with long COVID neurological symptoms.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-05-26; most recent amendment 2025-04-08.
Status change: Recruiting → Active, Not Recruiting 2025-04-08
Status change: Not Yet Recruiting → Recruiting 2022-05-02
Trial Details
NCT Number NCT04904536
Lead Sponsor The George Institute
Collaborators: University of Sydney, Monash University, The Alfred, Universidad del Desarrollo, Chinese University of Hong Kong, Clinica Alemana de Santiago
Conditions Neurocognitive Impairment, Mild
Enrollment 190 participants
Start Date 2022-03-10
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-10